Journal article
Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy
The Journal of pediatrics, Vol.255, pp.224-229.e1
04/2023
DOI: 10.1016/j.jpeds.2022.11.026
Abstract
The effects of riociguat, an oral-soluble guanylate-cyclase stimulator, were studied in 10 infants with chronic pulmonary arterial hypertension. Respiratory status (n = 8/10), right heart dilation (n = 7/10), function (n = 9/10), and chronic pulmonary arterial hypertension (n = 8/10) improved. Median decrement in systolic (12 [4, 14]), diastolic (14 [7, 20]), and mean arterial (14 [10, 17]) pressures were noted; no critical hypotension or hypoxemia occurred.
Details
- Title: Subtitle
- Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy
- Creators
- Regan E. Giesinger - University of IowaAmy H. Stanford - University of IowaBrady Thomas - University of IowaSteven H. Abman - University of Colorado DenverPatrick J. McNamara - University of Iowa
- Resource Type
- Journal article
- Publication Details
- The Journal of pediatrics, Vol.255, pp.224-229.e1
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.jpeds.2022.11.026
- ISSN
- 0022-3476
- eISSN
- 1097-6833
- Language
- English
- Electronic publication date
- 12/2022
- Date published
- 04/2023
- Academic Unit
- Stead Family Department of Pediatrics; Internal Medicine; Neonatology
- Record Identifier
- 9984354519802771
Metrics
28 Record Views